M&A Deal Summary

Pentixapharm Acquires Glycotope

On July 3, 2024, Pentixapharm acquired life science company Glycotope

Acquisition Highlights
  • This is Pentixapharm’s 1st transaction in the Life Science sector.
  • This is Pentixapharm’s 1st transaction in Germany.

M&A Deal Summary
Date 2024-07-03
Target Glycotope
Sector Life Science
Buyer(s) Pentixapharm
Deal Type Add-on Acquisition

Target

Glycotope

Berlin, Germany
Glycotope is an antibody development company specializing in innovative approaches to cancer immunotherapy. Glycotope is based in Berlin, Germany.

Search 199,165 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pentixapharm

Würzburg, Germany
Category Company
Sector Life Science
DESCRIPTION

Pentixapharm is a radiopharmaceutical company developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs in some hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases. Pentixapharm was founded in 2019 and is based in Würzburg, Germany.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Germany) 1 of 1
Year (2024) 1 of 1
Mergr

Product

Company

Legal